Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosisVINGARA, Lisa K; HUI JING YU; WAGSHULC, Mark E et al.NeuroImage (Orlando, Fla.). 2013, Vol 82, pp 586-594, issn 1053-8119, 9 p.Article

Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patientsSHUKLA, Dinesh K; KAISER, Claudia C; STEBBINS, Glenn T et al.Neuroscience letters. 2010, Vol 472, Num 3, pp 153-156, issn 0304-3940, 4 p.Article

Motor-dominant chronic inflammatory demyelinating polyneuropathyKIMURA, Akio; SAKURAI, Takeo; KOUMURA, Akihiro et al.Journal of neurology. 2010, Vol 257, Num 4, pp 621-629, issn 0340-5354, 9 p.Article

Elevated HSP27 levels during attacks in patients with multiple sclerosisCE, P; ERKIZAN, O; GEDIZLIOGLU, M et al.Acta neurologica scandinavica. 2011, Vol 124, Num 5, pp 317-320, issn 0001-6314, 4 p.Article

Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosisGORGORAPTIS, Nikos; WHEETER-KINGSHOTT, Claudia Am; JENKINS, Thomas M et al.Multiple sclerosis. 2010, Vol 16, Num 5, pp 555-565, issn 1352-4585, 11 p.Article

Early diffuse demyelinating lesion in the cervical spinal cord predicts a worse prognosis in relapsing―remitting multiple sclerosisCORET, F; BOSCA, I; LANDETE, L et al.Multiple sclerosis. 2010, Vol 16, Num 8, pp 935-941, issn 1352-4585, 7 p.Article

Cognitive impairments in relapsing-remitting multiple sclerosis : a meta-analysisPRAKASH, R. S; SNOOK, E. M; LEWIS, J. M et al.Multiple sclerosis. 2008, Vol 14, Num 9, pp 1250-1261, issn 1352-4585, 12 p.Article

Cortical dysfunction underlies disability in multiple sclerosisVUCIC, Steve; BURKE, Therese; LENTON, Kerry et al.Multiple sclerosis. 2012, Vol 18, Num 4, pp 425-432, issn 1352-4585, 8 p.Article

Cerebrospinal fluid CXCLI3 in multiple sclerosis: a suggestive prognostic marker for the disease courseKHADEMI, Mohsen; KOCKUM, Ingrid; ANDERSSON, Magnus L et al.Multiple sclerosis. 2011, Vol 17, Num 3, pp 335-343, issn 1352-4585, 9 p.Article

Pathophysiology of multiple sclerosis and the place of teriflunomideGOLD, R; WOLINSKY, J. S.Acta neurologica scandinavica. 2011, Vol 124, Num 2, pp 75-84, issn 0001-6314, 10 p.Article

Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapsePAPEIX, C; DEPAZ, R; TOURBAH, A et al.Multiple sclerosis. 2011, Vol 17, Num 12, pp 1520-1522, issn 1352-4585, 3 p.Article

Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosisDAVIES, G. R; ALTMANN, D. R; MILLER, D. H et al.Journal of neurology. 2005, Vol 252, Num 9, pp 1037-1044, issn 0340-5354, 8 p.Article

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawalDAELMAN, L; MAITROT, A; MAAROUF, A et al.Multiple sclerosis. 2012, Vol 18, Num 11, pp 1647-1649, issn 1352-4585, 3 p.Article

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational studyFERNANDEZ, Oscar; PAPAIS ALVARENGA, Marcos; FERNANDEZ, Victoria et al.Multiple sclerosis. 2011, Vol 17, Num 2, pp 192-197, issn 1352-4585, 6 p.Article

Erythrocyte membrane fatty acids in patients with multiple sclerosisHON, G. M; HASSAN, M. S; VAN RENSBURG, S. J et al.Multiple sclerosis. 2009, Vol 15, Num 6, pp 759-762, issn 1352-4585, 4 p.Article

Motor evoked potentials in clinically isolated syndrome suggestive of multiple sclerosisRICO, A; AUDOIN, B; FRANQUES, J et al.Multiple sclerosis. 2009, Vol 15, Num 3, pp 355-362, issn 1352-4585, 8 p.Article

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosisDEBOUVERIE, M; VANDENBERGHE, N; MORRISSEY, S. P et al.Multiple sclerosis. 2004, Vol 10, Num 4, pp 407-412, issn 1352-4585, 6 p.Article

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosisTUTUNCU, Melih; TANG, Junger; LUCCHINETTI, Claudia F et al.Multiple sclerosis. 2013, Vol 19, Num 2, pp 188-198, issn 1352-4585, 11 p.Article

Serum levels of LIGHT in MSMALMESTRÖM, Clas; GILLETT, Alan; WADENVIK, Hans et al.Multiple sclerosis. 2013, Vol 19, Num 7, pp 871-876, issn 1352-4585, 6 p.Article

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosisHOLMEN, Carolina; PIEHL, Fredrik; LYCKE, Jan et al.Multiple sclerosis. 2011, Vol 17, Num 6, pp 708-719, issn 1352-4585, 12 p.Article

Neutralizing antibodies to 500 μg interferon beta-1b: 28-month results of the IDEAS extension trialGOTTESMAN, M. H; FRIEDMAN-UREVICH, S; BOYLAN, E et al.Multiple sclerosis. 2010, Vol 16, Num 1, pp 78-80, issn 1352-4585, 3 p.Article

A method for evaluating treatment switching criteria in multiple sclerosisHEALY, Brian C; GLANZ, Bonnie I; STANKIEWICZ, James et al.Multiple sclerosis. 2010, Vol 16, Num 12, pp 1483-1489, issn 1352-4585, 7 p.Article

Assessing changes in relapse rates in multiple sclerosisINUSAH, Seidu; SORMANI, Maria P; COFIELD, Stacey S et al.Multiple sclerosis. 2010, Vol 16, Num 12, pp 1414-1421, issn 1352-4585, 8 p.Article

Effects of interferon beta-1a and -1b over time : 6-year results of an observational head-to-head studyPATTI, F; PAPPALARDO, A; FLORIO, C et al.Acta neurologica scandinavica. 2006, Vol 113, Num 4, pp 241-247, issn 0001-6314, 7 p.Article

Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosisDUDESEK, Ales; ZETTL, Uwe K.Journal of neurology. Supplement. 2006, Vol 253, Num 5, pp 50-58, issn 0939-1517, 9 p.Conference Paper